HiFiBiO Inc.

HiFiBiO Inc. is a biotherapeutics company dedicated to developing innovative immunotherapies utilizing advanced technologies to address unmet medical needs across various disease areas. Founded in 2013 in Cambridge, US, HiFiBiO Inc. specializes in biotherapeutics, focusing on immunotherapy development.

The company's CEO, Liang Schweizer, has driven its strategic initiatives, including a Series D funding round in June 2021, which raised USD 75 mn led by Mirae Asset Venture Investment, with participation from notable investors. HiFiBiO has successfully completed four funding rounds to date, with this latest round marking the total amount raised at USD 75 mn. HiFiBiO Therapeutics is focused on developing innovative immunotherapies that address significant unmet medical needs in various disease areas. Central to their offerings is the Drug Intelligence Science (DIS®) platform, which leverages advanced single-cell technology and AI/ML analytics to gain insights into cellular pathology.

This platform underpins their efforts in target discovery, antibody selection, and predictive biomarker identification, ultimately designed to enhance clinical outcomes for patients. The company’s therapeutic candidates are aimed at treating conditions such as cancer and autoimmune diseases, with a developmental focus primarily in North America and Europe. The end users of HiFiBiO's products include healthcare providers and patients in clinical settings, who benefit from more personalized and effective treatment options. HiFiBiO Therapeutics generates revenue through strategic partnerships and collaborations in the biotechnology and pharmaceutical sectors.

The company engages in B2B transactions, often establishing agreements with research institutions and pharmaceutical companies for the development of its clinical candidates derived from the DIS® platform. These partnerships may involve milestone payments and royalties associated with successful therapeutic developments. Specific pricing structures are typically negotiated as part of these collaborations, reflecting the value of their proprietary technologies and therapeutic innovations. The firm’s financial transactions are structured to align with the progress of their clinical programs, thereby enhancing their revenue potential as they advance toward market-ready solutions.

HiFiBiO Inc. plans to utilize the USD 75 mn raised in Series D funding to advance two lead antibody oncology assets into Phase I clinical trials – HFB200301, a novel anti-TNFR2 antibody, and HFB301001, a differentiated second-generation anti-OX-40 antibody. The company is also exploring opportunities to expand its reach into new markets, particularly in Europe and Asia, within the next two years, aiming to enhance access to its innovative therapeutic solutions.